European reference network for rare vascular diseases (VASCERN): When and how to use intravenous bevacizumab in Hereditary Haemorrhagic Telangiectasia (HHT)?

Sophie Dupuis-Girod*, Claire L Shovlin, Anette D Kjeldsen, Hans-Jurgen Mager, Carlo Sabba, Freya Droege, Anne-Emmanuelle Fargeton, Annette D Fialla, Silvia Gandolfi, Ruben Hermann, Gennaro M Lenato, Guido Manfredi, Marco C Post, Catherine Rennie, Patrizia Suppressa, Ulrich Sure, Elisabetta Buscarini*, ePag group

*Kontaktforfatter

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Abstrakt

Hereditary haemorrhagic telangiectasia (HHT) is a rare vascular multisystemic disease that leads to epistaxis, anaemia due to blood loss, and arteriovenous malformations (AVMs) in organs such as the lungs, liver and brain. HHT prevalence is estimated at 1/6000, i.e. around 85,000 European citizens, and is served by the European Reference Network for Rare Multisystemic Vascular Diseases (VASCERN). HHT treatments depend on clinical manifestations, and span multiple different medical, surgical and interventional disciplines. Separate to local treatments in the nose, in severe settings, intravenous bevacizumab has been proposed as treatment option, and the purpose of the current article is to assess the use of intravenous bevacizumab in patients with HHT in 2022 according to available data.

OriginalsprogEngelsk
Artikelnummer104575
TidsskriftEuropean Journal of Medical Genetics
Vol/bind65
Udgave nummer10
ISSN1769-7212
DOI
StatusUdgivet - okt. 2022

Bibliografisk note

Copyright © 2022 Elsevier Masson SAS. All rights reserved.

Fingeraftryk

Dyk ned i forskningsemnerne om 'European reference network for rare vascular diseases (VASCERN): When and how to use intravenous bevacizumab in Hereditary Haemorrhagic Telangiectasia (HHT)?'. Sammen danner de et unikt fingeraftryk.

Citationsformater